Sanofi (EPA:SAN) Given a €87.00 Price Target by UBS Group Analysts

UBS Group set a €87.00 ($101.16) price target on Sanofi (EPA:SAN) in a research note released on Wednesday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on the company. JPMorgan Chase & Co. set a €81.00 ($94.19) price target on Sanofi and gave the company a neutral rating in a research note on Tuesday, July 30th. HSBC set a €79.00 ($91.86) price target on Sanofi and gave the company a neutral rating in a research note on Friday, August 2nd. Jefferies Financial Group set a €90.00 ($104.65) price target on Sanofi and gave the company a buy rating in a research note on Friday, June 21st. Credit Suisse Group set a €82.00 ($95.35) price target on Sanofi and gave the company a buy rating in a research note on Tuesday, July 30th. Finally, Oddo Bhf set a €94.00 ($109.30) price objective on Sanofi and gave the stock a buy rating in a research note on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of €86.29 ($100.33).

Sanofi stock opened at €75.99 ($88.36) on Wednesday. The company has a 50-day simple moving average of €75.25. Sanofi has a one year low of €63.09 ($73.36) and a one year high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Further Reading: What is the Quick Ratio?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.